Yiseng US Biopharma is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics for infectious diseases and cancer. With a dedicated team of over 800 employees and a presence in multiple countries, including China, Singapore, the United States, the United Arab Emirates, and the Philippines, Yiseng US Biopharma utilizes its proprietary PIKA immunomodulating technology platform to develop a diverse range of biotherapeutics targeting diseases such as COVID-19, hepatitis B, rabies, flu, and various forms of cancer. Through their PIKA technology, which activates multiple pathways of immune signaling, including TLR3, RIG-I, and MDA5, Yiseng US Biopharma is at the forefront of developing innovative antiviral vaccines, antiviral therapeutics, and anticancer therapeutics. Their pipeline includes PIKA-based vaccines for infectious diseases and PIKA-based immuno-oncology candidates that have demonstrated potent antitumor effects in preclinical studies. With a strong focus on advancing novel immunotherapeutics, Yiseng US Biopharma is committed to making significant contributions to the field of biopharmaceuticals.Generated from the website

Cassidy Turley Midwest

FedEx

Tonya Harris, Bankers Life Agent

Brows N Babes